Under-the-Radar Shifts: From AI Infrastructure Pivots to Niche ETFsGlobal Report·2 days ago, 04:12 AMCRS-5.35%DWTX+2.60%
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026Unusual Whales·Jul 20 at 07:32 AMDWTX+2.60%
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipelinePUBT·Jun 30 at 07:37 PMDWTX+2.60%
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board | DWTX Stock NewsStockTitan·Jun 29 at 11:45 PMDWTX+2.60%
Dogwood Therapeutics shareholders approve charter amendment increasing authorized sharesPUBT·Jun 17 at 03:56 PMDWTX+2.60%
12:31 ETChemotherapy-Induced Peripheral Neuropathy Market to Witness Significant Growth at a CAGR of 14.2% During the Forecast Period (2026-2036) as Novel Therapies Enter Late-Stage Development | DelveInsightprnewswire·Jun 16 at 11:32 AMDWTX+2.60%
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock NewsStockTitan·May 17 at 11:45 PMDWTX+2.60%IXJ-1.15%
Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q SummaryTradingView·May 15 at 08:31 AMDWTX+2.60%LABU+7.39%
